ClinicalTrials.gg
CompletedNCT00730951Updated Jul 31, 2015

The Evaluation and Standardization of Ginseng and Its Components for Blood Pressure Regulation

A Phase 2 interventional study of Korean Red Ginseng and Corn Starch in Hypertension, sponsored by Unity Health Toronto. Completed at 1 site in Canada. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-07-31.

Sponsored by Unity Health Toronto · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

While the use of herbals is increasing considerably, their efficacy and safety in the humans remains largely unknown. This surge in demand prompts a call for its evaluation. Preliminary data demonstrates that KRG can affect vascular function and our research group has previously shown that Korean Red Ginseng (KRG) can lower blood pressure (BP) in hypertensive individuals. However, it is unknown which dose is the most effective in producing a desired effect. To address this issue, we will test escalating doses of a single Korean red ginseng batch of 0.5g, 1g 3g and 6g on BP in patients with hypertension to determine the most efficacious dose. The most promising dose will be extracted and will advance to next level to be tested again on BP control. The findings of the study may result in better ginseng standardization.

Read the detailed description

Individuals will arrive at the Risk Factor Modification Centre, St. Michael's Hospital between the hours of 8:00 and 10:00am after a 10 to 12-hour fast on seven separate mornings. They will not have consumed any antihypertensive medications on the study mornings. Each visit will be separated by a minimum of a week. Since the half-life of ginsenosides in humans is less than 24-hours, to allow for a washout of approximately seven half-lives.

In each of the four studies, when individuals arrive at our clinic on a test day they will first have their weight measured and subsequently rest in the seated position. They will then have a catheter inserted into a forearm vein, which will be kept patent by saline. From this device, a registered intravenous nurse will obtain a series of 7ml blood samples. Blood will be taken at 30-min intervals. Subsequently, individuals will fill out forms detailing their pharmacological regimen for the previous 24-hours and their diet (dinner) and activity (sleep, urination, morning routine) regimen for the previous 12-hours. As well, they will detail any adverse events that they experienced since their previous visit. Individuals will then have their office BP measured with a mercury sphygmomanometer until three consecutive measurements of both SBP and DBP \<5 mmHg different are obtained. At this point, BP should be steady and subjects will be fitted with an ABPM. Measurements will be taken every 5-min for 30-min, for a total of seven measurements. After the seventh measurement (time 0-min), measurements will be taken automatically every 10-min for 180-min. At time 0-min, treatment or placebo capsules will be consumed. At time 60-min a 360-calorie Ensure® breakfast will be consumed within 5-min. Blood samples will be drawn at 30-min intervals, starting at time 0-min. For 24-hours after the ingestion of treatment, a record of any side effects will be detailed by the participants and then provided to us.

02

Conditions studied

  • Hypertension

Browse trials for

03

In context

Hypertension

6,834 studies on the registry are indexed under Hypertension; 971 are open to participants now.

This study's enrollment of 18 is below the median of 90 across 5,095 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Unity Health Toronto is the lead sponsor of 444 studies on the registry; 80 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Essential Hypertension

Exclusion criteria

Exclusion Criteria:

  • Secondary Hypertension
  • Diabetes
  • Chronic Kidney Disease
  • Liver Disease
  • Unstable Angina
  • Coronary / Cerebrovascular event in the previous 6 months
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    1

    0.5g Korean Red Ginseng (1 capsule) 5.5g Corn Starch (11 capsules)

    Dietary Supplement: Korean Red Ginseng · Dietary Supplement: Corn Starch

  • Experimental
    2

    1g Korean Red Ginseng (2 capsules) 5g Corn Starch (10 capsules)

    Dietary Supplement: Korean Red Ginseng · Dietary Supplement: Corn Starch

  • Experimental
    3

    3g Korean Red Ginseng (6 capsules) 3g Corn Starch (6 capsules)

    Dietary Supplement: Korean Red Ginseng · Dietary Supplement: Corn Starch

  • Experimental
    4

    6g Korean Red Ginseng (12 capsules)

    Dietary Supplement: Korean Red Ginseng

  • Experimental
    5

    6g Corn Starch Control (12 capsules)

    Dietary Supplement: Corn Starch

Interventions

  • Dietary supplementKorean Red Ginseng

    500mg Capsulated Ground Dried Korean Red Ginseng Root

  • Dietary supplementCorn Starch

    500mg Capsulated Corn Starch

06

What researchers measure

Primary outcomes

  1. Blood Pressure will be measured with an Ambulatory Blood Pressure Monitor

    Time frame: every 5 min for first 30 min, then every 10 minutes for 180 minutes

Secondary outcomes

  1. Blood samples will be drawn and tested for Nitric Oxide levels.

    Time frame: every 30 minutes

07

Study locations

1 site
  • Clinical Nutrition and Risk Factor Modification Centre
    Toronto, Ontario, Canada
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 31, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00730951
Collaborators
Heart and Stroke Foundation of Ontario
Responsible party
Sponsor
First posted
Aug 8, 2008
Start date
Jun 2007
Primary completion
Jan 2008
Completion
Mar 2008
Last update
Jul 31, 2015

Study contacts

Vladimir Vuksan, PhD
principal investigator · Clinical Nutritian and Risk Factor Modification Centre

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Asian ginseng · Starch

Start the discussion